Carlos D. M.
- Country
- Spain
- Department
- Haematology
Research Overview
- Phase 3 Study of Quizartinib with Chemotherapy in FLT3-ITD Negative Acute Myeloid Leukemia Patients
- A randomized phase III, global, multicentre, open label clinical trial comparing Venetoclax Azacitidine and Quizartinib vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy.
Data & Insights
Has run more than one trial at 17 of 129 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in the treatment of acute myeloid leukemia (AML), with particular focus on developing innovative therapeutic approaches for newly diagnosed patients.
- Blood Cancer Treatment
- Leukemia Management
- Targeted Therapy Development
Primary research interest centers on investigating combination therapies involving standard chemotherapy protocols alongside novel therapeutic agents.
Personalized Medicine
The investigator focuses on advancing treatment strategies for patients with specific molecular profiles, particularly those with FLT3-ITD negative AML.
- Molecular Profiling
- Treatment Optimization
- Patient Stratification
Expertise includes developing therapeutic approaches that consider individual patient genetic characteristics in blood cancer treatment.
Treatment Innovation
Research activities concentrate on evaluating novel therapeutic combinations incorporating maintenance therapy approaches in hematologic malignancies.
- Clinical Innovation
- Treatment Duration Studies
- Therapeutic Combinations
The investigator explores extended treatment protocols aimed at improving patient outcomes in acute leukemia.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.